Literature DB >> 2923388

The two-period crossover design in medical research.

J R Woods1, J G Williams, M Tavel.   

Abstract

The crossover design has enjoyed popularity with many clinical researchers, but has been criticized by biostatisticians. The central problem is the inability to derive an unbiased estimate of the treatment effect when differences occur because of the different sequences in which treatments are applied. This problem can be traced to a deficiency of the logic of the crossover arrangement itself. Factors that can invalidate the findings of a crossover trial include nonuniform pharmacologic and psychologic carry-over effects, failure to return patients to their baseline state before the crossover, nonuniform changes in the patients over time, and the use of time-dependent response measures. When these problems can be anticipated, a parallel-groups design should be used instead of a crossover trial.

Entities:  

Mesh:

Year:  1989        PMID: 2923388     DOI: 10.7326/0003-4819-110-7-560

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

1.  Design of treatment trials for functional gastrointestinal disorders.

Authors:  S J Veldhuyzen van Zanten; N J Talley; P Bytzer; K B Klein; P J Whorwell; A R Zinsmeister
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  Evaluation of a computerized diagnostic decision support system for patients with pneumonia: study design considerations.

Authors:  D Aronsky; K J Chan; P J Haug
Journal:  J Am Med Inform Assoc       Date:  2001 Sep-Oct       Impact factor: 4.497

Review 3.  Randomised controlled trials in primary care: scope and application.

Authors:  Aziz Sheikh; Liam Smeeth; Richard Ashcroft
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

4.  Critical appraisal of medical literature: second update.

Authors:  M Labrecque; R Verreault; I Grava-Gubins
Journal:  Can Fam Physician       Date:  1990-10       Impact factor: 3.275

5.  The effect of fish oil supplements on blood pressure.

Authors:  R P Lofgren; T J Wilt; K L Nichol; L Crespin; R Pluhar; J Eckfeldt
Journal:  Am J Public Health       Date:  1993-02       Impact factor: 9.308

6.  Lactobacillus paracasei subsp. paracasei LC01 positively modulates intestinal microflora in healthy young adults.

Authors:  Hao Zhang; Jing Sun; Xianting Liu; Chuan Hong; Yuanbo Zhu; Aiping Liu; Siqi Li; Huiyuan Guo; Fazheng Ren
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

7.  A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.

Authors:  Henry E Wiley; Darby J S Thompson; Clare Bailey; Emily Y Chew; Catherine A Cukras; Glenn J Jaffe; Richard W J Lee; Erin K Loken; Catherine B Meyerle; Wai Wong; Frederick L Ferris
Journal:  Ophthalmology       Date:  2016-02-10       Impact factor: 12.079

Review 8.  Cannabinoid-based medicines for neurological disorders--clinical evidence.

Authors:  Stephen Wright
Journal:  Mol Neurobiol       Date:  2007-06-29       Impact factor: 5.590

9.  A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial.

Authors:  Solveig C Ligaarden; Lars Axelsson; Kristine Naterstad; Stian Lydersen; Per G Farup
Journal:  BMC Gastroenterol       Date:  2010-02-10       Impact factor: 3.067

10.  Between-subject and within-subject variations in the pharmacokinetics of ethanol.

Authors:  A W Jones; K A Jönsson
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.